TICKERNERD
Menu
ATOSATOSHealthcare · Biotechnology

ATOS Stock Forecast: Atossa Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.54
−2.12% on the day

The 2 Wall Street analysts covering Atossa Therapeutics, Inc. hold a median 12-month price target of $22 — +767.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$25.3M
Ticker Nerd rank
23 / 100
Median analyst target
$22
Analysts covering
2
Total return, dividends reinvested
1W
−2.5%
1M
+5.6%
YTD
−71.4%
1Y
−77.2%
From 52W high
−85.7%
From 52W low
+44.9%
$2
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ATOS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Atossa Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
87
Revisions
72
Accruals
46
Volatility
41
Issuance
40
Quality
33
Value
12
Growth
10
Momentum
2

Size (87): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ATOS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATOS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26ATOSHigh $24Median $22Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $10Median $22High $24

The green dot is the last close — the median target sits +767.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 July 2026Rodman & RenshawInitiatesBuy—
7 July 2026Rodman & RenshawInitiatesBuy$12
10 Apr 2026Ascendiant CapitalMaintainsBuy—
26 Mar 2026HC Wainwright & Co.MaintainsBuy—
8 Dec 2025Ascendiant CapitalMaintainsBuy—
22 Sept 2025Ascendiant CapitalMaintainsBuy—
6 June 2025Ascendiant CapitalMaintainsBuy—
5 June 2025Craig-HallumInitiatesBuy—
21 Apr 2025Ascendiant CapitalMaintainsBuy—
26 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025HC Wainwright & Co.ReiteratesBuy—
13 Dec 2024HC Wainwright & Co.ReiteratesBuy—
12 Dec 2024HC Wainwright & Co.ReiteratesBuy—
9 Dec 2024Ascendiant CapitalMaintainsBuy—
13 Nov 2024HC Wainwright & Co.MaintainsBuy—
5 Nov 2024HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024HC Wainwright & Co.ReiteratesBuy—
11 Sept 2024Ascendiant CapitalMaintainsBuy—
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ATOS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ATOS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Atossa Therapeutics, Inc. (ATOS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 81% of US stocks

Price / sales
—
Price / book
0.9×

Cheaper than 75% of US stocks

EV / EBITDA
0.0×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−89.2%

Higher than 14% of US stocks

Return on assets
−50.7%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ATOS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATOSAtossa Therapeutics, Inc.$25.3M
23
GRDXGridAI Technologies Corp.$25.3M
38
CVMCEL-SCI Corp.$24.8M
34
TVRDTvardi Therapeutics, Inc.$24.8M
28
ENLVEnlivex Ltd.$24.7M
31
CLRBCellectar Biosciences, Inc.$24.5M
25
LGVNLongeveron, Inc.$26.3M
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Atossa Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATOS news & analysis

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

PRNewsWire · 7 Aug 2026neutral

Atossa Therapeutics announced its financial results for the second quarter ended June 30, 2026, and provided an update on recent corporate developments. The company described its execution during the quarter as strong.

Why it matters — The financial results and corporate update offer ATOS watchers insight into the company's recent operational progress and financial health as a clinical-stage biopharmaceutical company.

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

PRNewsWire · 28 July 2026positive

Atossa Therapeutics announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel (Z)-endoxifen-related compounds, which demonstrated potent anti-estrogenic and anti-cancer activity across multiple estrogen receptor-positive breast cancer models, including those with ESR1 mutations.

Why it matters — ATOS watchers would care because this peer-reviewed publication validates the potential of the company's pipeline of novel (Z)-endoxifen-related compounds in addressing ER-positive breast cancer, including treatment-resistant ESR1-mutant models.

FAQ

Frequently asked questions about ATOS stock

What is the ATOS stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Atossa Therapeutics, Inc. have a median 12-month price target of $22, with estimates ranging from $10 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATOS stock a buy right now?

Of the 2 analysts covering Atossa Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atossa Therapeutics, Inc. 23 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATOS?

As at 22 Aug 2026, Atossa Therapeutics, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

Will ATOS stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +767.9% from the last close, and Ticker Nerd's factor model ranks Atossa Therapeutics, Inc. 23 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATOS stock forecast for 2030?

No analyst covering Atossa Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $24 over the next 12 months.

How has ATOS stock performed over the past year?

Atossa Therapeutics, Inc. returned -77.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Atossa Therapeutics, Inc. do?

Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods primarily for the treatment of breast cancer and other breast conditions.

What is the latest news on ATOS?

The most recent item we track (PRNewsWire, 7 Aug 2026): "Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update". Atossa Therapeutics announced its financial results for the second quarter ended June 30, 2026, and provided an update on recent corporate developments. The company described its execution during the quarter as strong.

Company

About Atossa Therapeutics, Inc.

Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods primarily for the treatment of breast cancer and other breast conditions. Its lead candidate, Endoxifen, targets these areas to address unmet medical needs in oncology. The company also pursues proprietary medicines in oncology more broadly, focusing on innovative approaches to improve patient outcomes. Atossa Therapeutics Inc. operates in the pharmaceutical sector, emphasizing drug development for breast-related disorders through clinical programs. Founded in 2008 and headquartered in Seattle, Washington, it advances its pipeline through research and clinical trials, contributing to advancements in breast cancer therapies within the biopharmaceutical market.

CEO Dr. Steven C. Quay FCAP, M.D., Ph.D. · 16 employees · United States · https://www.atossatherapeutics.com